Crizotinib API Manufacturers & Suppliers

Crizotinib (CAS Number 877399-52-5) is a small molecule tyrosine kinase receptor inhibitor indicated primarily for the treatment of metastatic non-small cell lung cancer (NSCLC) characterized by anaplastic lymphoma kinase (ALK) or ROS1-positive tumor rearrangements as confirmed by FDA-approved diagnostic tests. Additional approved indications include relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL) in pediatric patients aged one year and older and young adults, as well as unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) in both adult and pediatric populations with ALK-positive status.

Pharmacodynamically, crizotinib inhibits oncogenic fusion proteins resulting from ALK gene translocations, most notably the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion prevalent in a subset of NSCLC cases. Clinical studies demonstrated a progression-free survival of approximately 72% at six months and improved two-year overall survival rates compared to untreated ALK-positive patients. The compound displays inhibitory activity against multiple kinases including ALK, c-MET (hepatocyte growth factor receptor), ROS1, and RON, thereby obstructing receptor phosphorylation and downstream signaling pathways that promote tumor cell proliferation and survival.

Crizotinib is classified chemically as a pyrazolylpyridine derivative. Its mechanism of action centers on disrupting kinase autophosphorylation and stabilizing inactive protein conformations in fusion-positive tumor cells, thereby reducing malignant growth.

Regarding absorption, distribution, metabolism, and excretion (ADME) properties, crizotinib is metabolized predominantly via cytochrome P450 isoenzymes CYP3A4 and CYP3A5, serving also as a moderate inhibitor of these enzymes. This enzymatic interaction necessitates careful consideration of potential drug-drug interactions. Crizotinib is a substrate and inhibitor of P-glycoprotein and organic cation transporters, which may influence its pharmacokinetic profile and systemic exposure.

Safety concerns include risks of hepatotoxicity, interstitial lung disease, pneumonitis, QT interval prolongation, bradycardia, severe visual disturbances, gastrointestinal toxicity, and embryo-fetal toxicity. Close monitoring during treatment is essential, particularly in pediatric and young adult populations.

Crizotinib was first approved by the FDA in 2011 and retains significance as a first-in-class ALK inhibitor, although subsequent generations have been developed to overcome resistance mechanisms associated with its use.

For API sourcing and quality assurance, stringent adherence to Good Manufacturing Practice (GMP) standards is critical to ensure consistent purity, potent biological activity, and compliance with regulatory requirements. Due to its narrow therapeutic index and complex kinase-inhibitory profile, thorough impurity profiling and stability testing are recommended. Suppliers should provide comprehensive documentation, including certificates of analysis aligned with pharmacopeial standards, to support downstream formulation and regulatory processes.